Talaris Therapeutics (TALS) Gets a Buy Rating from Evercore ISI

In a report released today, Joshua Schimmer from Evercore ISI maintained a Buy rating on Talaris Therapeutics (TALSResearch Report), with a price target of $25.00. The company’s shares closed last Tuesday at $8.12, close to its 52-week low of $6.34.

According to, Schimmer is a 4-star analyst with an average return of 8.0% and a 49.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Talaris Therapeutics with a $23.50 average price target, implying a 189.4% upside from current levels. In a report issued on March 17, Leerink Partners also reiterated a Buy rating on the stock with a $22.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $19.82 and a one-year low of $6.34. Currently, Talaris Therapeutics has an average volume of 50.47K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Read More on TALS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed